Jackson Hole Capital Partners LLC Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Jackson Hole Capital Partners LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,592 shares of the biopharmaceutical company’s stock after purchasing an additional 1,241 shares during the quarter. Jackson Hole Capital Partners LLC’s holdings in Gilead Sciences were worth $1,587,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Clearbridge Investments LLC raised its holdings in shares of Gilead Sciences by 179.0% in the 3rd quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock valued at $340,526,000 after buying an additional 2,915,141 shares during the period. abrdn plc raised its holdings in shares of Gilead Sciences by 89.0% in the 4th quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock valued at $304,930,000 after buying an additional 1,772,887 shares during the period. International Assets Investment Management LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $133,584,000. AEGON ASSET MANAGEMENT UK Plc purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $63,971,000. Finally, Bailard Inc. raised its holdings in shares of Gilead Sciences by 9,100.7% in the 3rd quarter. Bailard Inc. now owns 722,345 shares of the biopharmaceutical company’s stock valued at $54,133,000 after buying an additional 714,494 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent research reports. UBS Group cut their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Wells Fargo & Company cut their price target on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. StockNews.com downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, April 19th. Mizuho cut their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Finally, Oppenheimer restated an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a report on Friday, April 19th. Ten investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $84.57.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $1.81 during trading hours on Thursday, reaching $65.27. The stock had a trading volume of 15,163,484 shares, compared to its average volume of 7,415,576. The firm has a market cap of $81.27 billion, a price-to-earnings ratio of 14.50, a PEG ratio of 0.96 and a beta of 0.19. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a fifty-two week low of $65.09 and a fifty-two week high of $87.86. The firm has a 50-day moving average of $71.40 and a 200-day moving average of $76.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. During the same period last year, the firm earned $1.37 EPS. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. Equities research analysts predict that Gilead Sciences, Inc. will post 5.24 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.72%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s dividend payout ratio is 68.44%.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.